Sutro Biopharma(STRO) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights - Expects to deliver three Investigational New Drug (IND) applications in next three years based on nextgeneration ADC technology - -Two new clinical trials, REFRαME-P1, a registration-enabling trial of luvelta for pediatric patients with rare leukemia, and REFRαME-L1, a Phase 2 trial of luvelta for patients with non-small cell lung cancer, are underway - - Sutro presented data from the Phase 1b study of luvelt ...